mau868
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 15, 2018 (NCT03456999)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- BK virusImmunity, passive
BK virus immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04294472 | Phase 2 | Apr 30, 2020 | Amplyx Pharmaceuticals |
| NCT03456999 | Phase 2 | Oct 15, 2018 | Novartis |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Amplyx Pharmaceuticals | For profit | 1 | 1 | 1 | 2020 |
| Novartis | For profit | 1 | 1 | 1 | 2018 |
2 organizations
Page 1 / 1